Royalty Purchase Agreements (Details) - Royalty Purchase Agreement - USD ($) $ in Millions		1 Months Ended	3 Months Ended
	Apr. 29, 2024	Apr. 29, 2024	Jun. 30, 2024	Dec. 31, 2024
XACIATO
Commitments And Contingencies [Line Items]
Transaction costs			$ 1.6
Synthetic
Commitments And Contingencies [Line Items]
Proceeds from sale of royalty and milestone rights			$ 22.0
XOMA
Commitments And Contingencies [Line Items]
Proceeds from royalties received		$ 22.0
Maximum royalty payments	$ 88.0	88.0
Contingent purchase price payments	11.0	11.0
Revenue tier threshold, upper range limit	$ 22.0	$ 22.0		$ 22.0
XOMA \| XACIATO
Commitments And Contingencies [Line Items]
Milestone payments rate	100.00%	100.00%
XOMA \| Ovaprene
Commitments And Contingencies [Line Items]
Net royalty payments rate	4.00%	4.00%
XOMA \| Sildenafil Cream, 2.0%
Commitments And Contingencies [Line Items]
Future net sales	0.020	0.020
XOMA \| Sildenafil Cream, 3.6%
Commitments And Contingencies [Line Items]
Maximum royalty payments	$ 110.0	$ 110.0
XOMA \| Sildenafil Cream, 3.6% \| Maximum
Commitments And Contingencies [Line Items]
Percentage of royalty rate	2.50%
XOMA \| Sildenafil Cream, 3.6% \| Minimum
Commitments And Contingencies [Line Items]
Percentage of royalty rate	1.25%
Bayer
Commitments And Contingencies [Line Items]
Potential future payment, percentage	0.25	0.25
Potential future payment	$ 20.0